Erfahrungen mit der adjuvanten Intron-A-Hochdosistherapie nach Kirkwood bei Hochrisikomelanomen der Stadien IIIa, IIIb und IV

Autor:	M. Suckow, Lutz Kowalzick, T. Waldmann, J.-M. Pönnighaus, Susanne Suckow
Rok vydání:	2002
Předmět:	Chemotherapy medicine.medical_specialty business.industry medicine.medical_treatment Melanoma Alpha interferon Dermatology medicine.disease Relapse free survival Surgery Metastasis Medicine In patient business Adjuvant Interferon alfa medicine.drug
Zdroj:	Aktuelle Dermatologie. 28:21-24
ISSN:	1438-938X 0340-2541
DOI:	10.1055/s-2002-21807
Popis:	In patients with malignant melanoma suffering from local, regional or distant metastasis the question of an adjuvant treatment modality arises following surgical removement of detectable tumor because of the high risk of tumor relapse. We report on our experiences with interferon alpha 2b (Intron A®)-high dose therapy according to Kirkwood in 22 patients over a time period of 4 years. In 4 patients (18%) therapy was discontinued on early during the i.v.-treatment phase because of side effects. In 11 patients (50%) the interferon dose had to be reduced during the i.v.-therapy phase, and in 4 patients (22 %) during the s.c.-therapy phase. In 5 patients (36%) a tumor relapse occurred during the s.c.-therapy phase. Four relapse free patients are still within the s.c.-therapy phase. In the 14 patients whose treatment is finished or terminated according to protocol the median relapse free survival time is now 19 months (1.58 years), and their overall survival now at least 27 months (2.25 years).
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::12b41b134853d552604188ca25d604a8 https://doi.org/10.1055/s-2002-21807 Zobrazit plný text záznamu